Loading stock analysis…
Evidence Synthesis
Last synthesized: 20 Oct 2026, 09:36
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence velocity
Rate-of-change signals for this ticker unlock with Pro — or view flagship demos TCS / RELIANCE.
Evidence Synthesis
Pharmaxis Limited Sees Accelerating Gross Margin Amid Decelerating Revenue Growth Pharmaxis Limited (PHRMASI) reported a quarterly Gross Margin of 29.09%, accelerating from 3.81%.
This represents a increase. The company's Marginal Operating Leverage decreased to , decelerating from 36.29%. Revenue Growth Yoy declined to , down from 25%. Daily Volume decreased to 347 shares, down 17.8% from the previous reading. The stock's Close Price remained unchanged at 80 INR.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 29.09 % | 3.81 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 3.81 % | 36.29 | ▼ |
| REVENUE_GROWTH_YOY | 20.5 % | 25 | ▼ |
| PRICE_CHANGE_PERCENT | 0 % | — | - |
| DAILY_VOLUME | 347 shares | 613 | ▼ |
| CLOSE_PRICE | 80 INR | 80 | - |
Cite this
Source: Samhati evidence synthesis for PHRMASI (2026-10-20). Observation: Pharmaxis Limited Sees Accelerating Gross Margin Amid Decelerating Revenue Growth Pharmaxis Limited (PHRMASI) reported a quarterly Gross Margin of 29.09%, accelerating from 3.81%. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/phrmasi
Filing step-changes